Estimating the Economically Justifiable Price of Limited-Duration Treatment with Donanemab for Early Symptomatic Alzheimer's Disease in the United States.
Saved in:
| Title: | Estimating the Economically Justifiable Price of Limited-Duration Treatment with Donanemab for Early Symptomatic Alzheimer's Disease in the United States. |
|---|---|
| Authors: | Boustani M; Division of Internal Medicine and Geriatrics, Indiana University School of Medicine, Indianapolis, IN, USA., Doty EG; Lilly Corporate Center, Indianapolis, IN, 46285, USA., Garrison LP Jr; Department of Pharmacy, The CHOICE Institute, University of Washington, Seattle, WA, USA., Smolen LJ; Medical Decision Modeling Inc, Indianapolis, IN, USA., Klein TM; Medical Decision Modeling Inc, Indianapolis, IN, USA., Murphy DR; Medical Decision Modeling Inc, Indianapolis, IN, USA., Spargo AW; Lilly Corporate Center, Indianapolis, IN, 46285, USA., Belger M; Eli Lilly and Company, Bracknell, UK., Johnston JA; Lilly Corporate Center, Indianapolis, IN, 46285, USA. johnston_joseph_a@lilly.com. |
| Source: | Neurology and therapy [Neurol Ther] 2024 Dec; Vol. 13 (6), pp. 1641-1659. Date of Electronic Publication: 2024 Sep 18. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Country of Publication: New Zealand NLM ID: 101637818 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2193-8253 (Print) Linking ISSN: 21936536 NLM ISO Abbreviation: Neurol Ther Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2193-8253 |
|---|---|
| DOI: | 10.1007/s40120-024-00649-y |
